{"disease":{"id":"high-risk-non-muscle-invasive-bladder-cancer","name":"high risk non muscle invasive bladder cancer"},"drugs":{"marketed":[{"drug_id":"bcg","indication_name":"Treatment of high-risk non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03711032","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1397,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07268339","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":328,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT06567743","title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":325,"lead_sponsor_name":"CG Oncology, Inc.","has_results":false},{"nct_id":"NCT07468851","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06108492","title":"A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03191578","title":"Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Archivel Farma S.L.","has_results":false},{"nct_id":"NCT06378242","title":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT06181266","title":"A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Prokarium Ltd","has_results":false},{"nct_id":"NCT07483970","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Jecho Biopharmaceuticals Co., Ltd.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}